Encourages students to think outside the box.
Dr. Jaslyn Kee serves as an Assistant Research Fellow in the Department of Pathology and Molecular Medicine at the University of Otago Christchurch, part of the Faculty of Medicine within the Health Sciences Division. She completed her PhD at the University of Otago Christchurch in 2023, with the thesis titled 'The Clinical Application of Pharmacogenetics in Understanding Drug Response,' supervised by Professor Martin Kennedy, Dr. Simone Cree, and Dr. Paul Chin. Her doctoral project examined the application of pharmacogenetics to adverse drug reactions. Prior to her PhD, Kee holds a Bachelor of Pharmacy. During her PhD, she was supported by a doctoral scholarship from the University of Otago and presented her research at the University of Otago Christchurch Research Seminar Series on 14 September as a PhD candidate alongside Mark Holdaway.
Kee's research focuses on pharmacogenetics, particularly genetic factors influencing drug metabolism and response in clinical contexts. Key areas include the pharmacogenetics of CYP2D6 and CYP2C19 in antidepressant responses (published 2023), omeprazole treatment failure in gastroesophageal reflux disease linked to genetic variation at the CYP2C locus (2022), allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Pacific peoples (2022), and pharmacogenetics of statin-induced myotoxicity (2020). Additional contributions encompass nanopore sequencing-based genotyping for CYP2D6 function and its relation to anxiety and depression susceptibility (2024 and 2025 publications), a chapter on long-range polymerase chain reaction (2023), and PCR enhancers for long-range PCR applications (2022). These works, published in journals such as Frontiers in Genetics, enhance understanding of pharmacogenomic variations in diverse populations, supporting personalized medicine in pharmacology. Her ResearchGate profile lists nine publications with 182 citations, reflecting emerging impact in the field.
